# ADVERSE_EVENT_REPORTING_PROTOCOL.md  
**Adverse Event Detection, Classification & Reporting Framework**

---

## 1. Purpose

This document establishes a formal protocol for the **identification, classification, documentation, escalation, and reporting** of adverse events associated with NeuroGrid systems, including AI models, RPM infrastructure, data pipelines, and governance mechanisms.

The objective is to:
- Protect patient safety
- Ensure regulatory compliance
- Enable rapid corrective action
- Maintain transparency and accountability
- Prevent recurrence of harm

---

## 2. Scope

This protocol applies to adverse events arising from:

- Remote Patient Monitoring (RPM)
- AI model outputs or failures
- Data integrity or availability issues
- Cybersecurity incidents affecting clinical data
- Governance or DAO-triggered system actions
- Human–AI interaction failures

Applies across:
- Clinical deployments
- Pilot programs
- Research environments
- Post-market operations

---

## 3. Definition of Adverse Event

An **Adverse Event (AE)** is any unintended incident associated with the use of NeuroGrid systems that:

- Results in harm or potential harm to a patient
- Delays or disrupts clinical care
- Causes incorrect, misleading, or missed alerts
- Breaches data privacy or security
- Undermines clinical decision-making

This includes both **actual harm** and **credible risk of harm**.

---

## 4. Adverse Event Categories

### A. Clinical Safety Events
- Missed critical alerts
- False reassurance
- Delayed escalation
- Incorrect monitoring interpretation

### B. AI & Algorithmic Events
- Model drift leading to unsafe outputs
- Incorrect pattern recognition
- Bias-induced misclassification
- Unapproved model behavior

### C. Technical & System Events
- Data loss or corruption
- System downtime
- Sensor malfunction
- Integration failures

### D. Data Protection Events
- Unauthorized data access
- Data leakage
- Consent violations

### E. Governance & Operational Events
- Unauthorized DAO actions
- Improper access permissions
- Funding or incentive misuse affecting care

---

## 5. Event Severity Classification

| Level | Severity | Description |
|-----|--------|------------|
| Level 1 | Critical | Serious injury, death, or immediate risk |
| Level 2 | High | Significant clinical risk or system failure |
| Level 3 | Moderate | Potential harm, recoverable issue |
| Level 4 | Low | No harm, procedural deviation |
| Level 5 | Near Miss | Risk identified before impact |

Severity determines escalation timelines.

---

## 6. Detection & Identification

Adverse events may be identified through:
- Automated system alerts
- Clinician reports
- Patient complaints
- Audit findings
- Monitoring dashboards
- External notifications

All detection sources are valid and must be logged.

---

## 7. Immediate Response Actions

Upon detection:
1. Ensure patient safety
2. Stabilize affected systems
3. Halt automated processes if necessary
4. Preserve logs and evidence
5. Notify responsible parties

No event may be dismissed without review.

---

## 8. Reporting Timelines

| Severity | Initial Report | Regulatory Notification |
|-------|---------------|-------------------------|
| Critical | Immediate (≤24h) | ≤24–72h |
| High | ≤48h | ≤7 days |
| Moderate | ≤5 days | As required |
| Low | ≤10 days | Not mandatory |
| Near Miss | Logged | Internal only |

Timelines align with jurisdictional requirements.

---

## 9. Internal Reporting Pathway

Reports must be submitted to:
- Compliance Lead
- Clinical Safety Officer
- Ethics Committee (if applicable)
- DAO Oversight Body (if governance-related)

All reports must be version-controlled.

---

## 10. External Reporting Obligations

When applicable, reports may be submitted to:
- Regulatory authorities (e.g., ANVISA, FDA, EMA)
- Institutional Review Boards (IRBs)
- Ethics committees
- Data protection authorities

Regulatory thresholds must be respected.

---

## 11. Root Cause Analysis (RCA)

All Level 1–3 events require:
- Formal RCA
- Systemic impact assessment
- Model behavior review (if AI-related)
- Governance review (if DAO-related)

Findings must be documented.

---

## 12. Corrective & Preventive Actions (CAPA)

CAPA may include:
- Model retraining or rollback
- System patches
- Policy updates
- Governance adjustments
- Staff retraining

Actions must be tracked to completion.

---

## 13. Patient & Stakeholder Communication

When required:
- Patients must be informed transparently
- Language must be factual and non-defensive
- No attribution of blame to patients
- Legal counsel involvement as appropriate

Communication must be documented.

---

## 14. Documentation & Recordkeeping

All adverse event records must include:
- Event description
- Date/time
- Systems involved
- Severity classification
- Actions taken
- Resolution status

Records must be retained per regulatory requirements.

---

## 15. Audit & Oversight

Adverse event handling is subject to:
- Internal audits
- External inspections
- Regulatory review
- DAO transparency mechanisms

Audit findings must inform improvements.

---

## 16. Regulatory Alignment

This protocol aligns with:
- ISO 14971 (Risk Management)
- ISO 62304 (Medical Software Lifecycle)
- FDA Medical Device Reporting (MDR)
- EU MDR vigilance requirements
- ANVISA vigilance systems
- LGPD / GDPR breach notification rules

---

## 17. Ethical Position

> **Silence after harm is itself a failure.  
> Transparency is a safety mechanism.**

---

## 18. Review & Update Cycle

Reviewed:
- Annually
- After critical events
- Following regulatory updates
- After major system changes

Amendments require compliance and ethics approval.

---

### Status
**Active – Mandatory Adverse Event Reporting Protocol**

Applies to all NeuroGrid clinical, research, and operational deployments.

